KR100966232B1 - 종양 및 세포의 제거 또는 파괴를 필요로 하는 다른질환의 치료에 효과적인 펩티드 - Google Patents

종양 및 세포의 제거 또는 파괴를 필요로 하는 다른질환의 치료에 효과적인 펩티드 Download PDF

Info

Publication number
KR100966232B1
KR100966232B1 KR1020047000844A KR20047000844A KR100966232B1 KR 100966232 B1 KR100966232 B1 KR 100966232B1 KR 1020047000844 A KR1020047000844 A KR 1020047000844A KR 20047000844 A KR20047000844 A KR 20047000844A KR 100966232 B1 KR100966232 B1 KR 100966232B1
Authority
KR
South Korea
Prior art keywords
leu
ser
ala
glu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020047000844A
Other languages
English (en)
Korean (ko)
Other versions
KR20040026686A (ko
Inventor
폴 에이. 아버백
잭 겜멜
Original Assignee
니목스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니목스 코포레이션 filed Critical 니목스 코포레이션
Publication of KR20040026686A publication Critical patent/KR20040026686A/ko
Application granted granted Critical
Publication of KR100966232B1 publication Critical patent/KR100966232B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
KR1020047000844A 2001-07-19 2002-07-19 종양 및 세포의 제거 또는 파괴를 필요로 하는 다른질환의 치료에 효과적인 펩티드 Expired - Lifetime KR100966232B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US30616101P 2001-07-19 2001-07-19
US30615001P 2001-07-19 2001-07-19
US60/306,150 2001-07-19
US60/306,161 2001-07-19
US33147701P 2001-11-16 2001-11-16
US60/331,477 2001-11-16
PCT/CA2002/001106 WO2003008444A2 (en) 2001-07-19 2002-07-19 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Publications (2)

Publication Number Publication Date
KR20040026686A KR20040026686A (ko) 2004-03-31
KR100966232B1 true KR100966232B1 (ko) 2010-06-25

Family

ID=27405149

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020047000844A Expired - Lifetime KR100966232B1 (ko) 2001-07-19 2002-07-19 종양 및 세포의 제거 또는 파괴를 필요로 하는 다른질환의 치료에 효과적인 펩티드
KR1020047000843A Expired - Fee Related KR101005130B1 (ko) 2001-07-19 2002-07-19 종양 및 세포의 제거 또는 파괴를 필요로 하는 다른질환의 치료에 효과적인 펩티드

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020047000843A Expired - Fee Related KR101005130B1 (ko) 2001-07-19 2002-07-19 종양 및 세포의 제거 또는 파괴를 필요로 하는 다른질환의 치료에 효과적인 펩티드

Country Status (22)

Country Link
US (2) US7241738B2 (enExample)
EP (2) EP1417227B1 (enExample)
JP (4) JP4587667B2 (enExample)
KR (2) KR100966232B1 (enExample)
CN (1) CN100475843C (enExample)
AT (1) ATE353914T1 (enExample)
AU (2) AU2002319049B2 (enExample)
BR (2) BRPI0211200B8 (enExample)
CA (2) CA2453967C (enExample)
CY (1) CY1108009T1 (enExample)
DE (2) DE60217507T2 (enExample)
DK (1) DK1417228T3 (enExample)
EA (1) EA006603B1 (enExample)
ES (2) ES2281529T3 (enExample)
IL (2) IL159903A0 (enExample)
MX (1) MXPA04000561A (enExample)
NO (1) NO333999B1 (enExample)
NZ (2) NZ531114A (enExample)
PL (1) PL207588B1 (enExample)
PT (1) PT1417228E (enExample)
WO (2) WO2003008443A2 (enExample)
ZA (1) ZA200401320B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050245451A1 (en) * 2000-04-05 2005-11-03 Pincus Matthew R Peptides selectively lethal to malignant and transformed mammalian cells
BR0207638A (pt) * 2001-03-08 2004-07-27 Nymox Pharmaceuticals Corp Métodos de uso de proteìna de filamento neural para tratar tumores e outras condições que requerem a remoção ou destruição de células
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
JP4587667B2 (ja) * 2001-07-19 2010-11-24 ナイモックス コーポレーション 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド
US7317077B2 (en) * 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
ATE445714T1 (de) * 2001-12-04 2009-10-15 Millennium Pharm Inc 15603, ein mitglied der humanen ionenkanal- familie
WO2005014635A2 (en) * 2003-07-15 2005-02-17 Genova Ltd. Secreted polypeptide species reduced in cardiovascular disorders
BRPI0412664A (pt) * 2003-07-15 2006-09-26 Ca Nat Research Council método para tratar uma condição caracterizada por hiperproliferação de células da pele em um indivìduo em risco ou portador dessa condição e utilização de uma quantidade terapeuticamente efetiva de um análogo cìclico de hormÈnio de paratireóide humano (hpth)
WO2005075647A1 (en) * 2004-02-06 2005-08-18 Nymox Corporation Humanized antibody
US20060173490A1 (en) 2005-02-01 2006-08-03 Boston Scientific Scimed, Inc. Filter system and method
PL1994152T3 (pl) 2006-02-28 2013-05-31 Nymox Corp Peptydy skuteczne w leczeniu nowotworów i innych stanów wymagających usunięcia lub zniszczenia komórek
MX2008011570A (es) * 2006-03-10 2008-09-23 Nymox Corp Metodo para prevenir o reducir el riesgo o incidencia de cancer usando peptidos basados en proteina de hebra neural.
US20080027005A1 (en) * 2006-07-31 2008-01-31 Paul Averback Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
CA2990264C (en) * 2007-10-25 2022-08-09 Toray Industries, Inc. Immune response inducer
JP5572938B2 (ja) * 2007-10-25 2014-08-20 東レ株式会社 免疫誘導剤
US9539327B2 (en) * 2007-11-26 2017-01-10 The Research Foundation For The State University Of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
EP2293809B1 (en) * 2008-04-24 2019-05-15 Therimunex Pharmaceuticals, Inc. Peptidyl diacylglycerides
US8637642B2 (en) 2010-09-29 2014-01-28 Seattle Genetics, Inc. Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
CA2928526A1 (en) 2013-11-01 2015-05-07 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
US20160215031A1 (en) * 2015-01-27 2016-07-28 Nymox Pharnaceutical Corporation Method of treating disorders requiring destruction or removal of cells
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11628202B2 (en) * 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) * 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) * 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
US10835538B2 (en) 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics
WO2019195851A1 (en) 2018-04-06 2019-10-10 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells
US20200061150A1 (en) 2018-08-23 2020-02-27 Nymox Corporation Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
AU2019392090A1 (en) 2018-12-03 2021-06-17 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
US20200360466A1 (en) 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
US11278588B2 (en) 2019-05-13 2022-03-22 Nymox Corporation Method of treating lower urinary tract symptoms with fexapotide triflutate
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US11331374B2 (en) 2019-07-31 2022-05-17 Nymox Corporation Focal treatment of prostate cancer
US11231421B2 (en) 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948888A (en) * 1988-12-21 1999-09-07 The General Hospital Corporation Neural thread protein gene expression and detection of Alzheimer's disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68927459T2 (de) * 1988-12-21 1997-04-24 Gen Hospital Corp Nachweis einer neurologischen Krankheit oder einer Funktionsstörung
KR20000075748A (ko) 1997-02-26 2000-12-26 마빈 씨. 구트리 알츠하이머 병의 치료 또는 예방에 유효한 약물을 선별하기 위한 유전자 변형동물 및 세포계
JP2002519311A (ja) * 1998-06-26 2002-07-02 ジョージタウン・ユニバーシティ・メディカル・センター 細胞死を誘発するための組成物と方法
US7125957B1 (en) * 1998-09-30 2006-10-24 Riken VPR mutant protein and its encoding gene having apoptosis-inducing action
WO2000034477A2 (en) 1998-12-11 2000-06-15 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
ES2202039T3 (es) * 1999-01-11 2004-04-01 Leadd B.V. Uso de agentes inductores de apoptosis en la preparacion de mrdicamentto para el tratamiento de enfermedades autoinmunitarias.
WO2000058339A2 (en) 1999-03-26 2000-10-05 Human Genome Sciences, Inc. 50 human secreted proteins
JP2002542766A (ja) 1999-03-12 2002-12-17 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 50個のヒト分泌タンパク質
AU3628600A (en) 1999-03-19 2000-10-09 Human Genome Sciences, Inc. 46 human secreted proteins
CA2368927A1 (en) 1999-03-26 2000-10-05 Craig A. Rosen 45 human secreted proteins
JP2002541833A (ja) 1999-03-26 2002-12-10 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 49個のヒト分泌タンパク質
CN1300779A (zh) 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽-人神经元线蛋白17和编码这种多肽的多核苷酸
CN1300783A (zh) 1999-12-23 2001-06-27 上海生元基因开发有限公司 新的人神经元线蛋白及其编码序列
EP1307488A2 (en) * 2000-06-26 2003-05-07 Millennium Pharmaceuticals, Inc. A human calcium channel protein and uses thereof
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
WO2002097030A2 (en) 2001-05-25 2002-12-05 Nymox Corporation Peptides derived from neural thread proteins and their medical use
JP4587667B2 (ja) * 2001-07-19 2010-11-24 ナイモックス コーポレーション 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948888A (en) * 1988-12-21 1999-09-07 The General Hospital Corporation Neural thread protein gene expression and detection of Alzheimer's disease

Also Published As

Publication number Publication date
DE60217507D1 (de) 2007-02-22
JP2013215191A (ja) 2013-10-24
IL159903A (en) 2010-02-17
WO2003008444A3 (en) 2003-11-20
CA2453967C (en) 2014-01-07
KR101005130B1 (ko) 2011-01-04
CA2453967A1 (en) 2003-01-30
CN1649895A (zh) 2005-08-03
ATE353914T1 (de) 2007-03-15
BRPI0211200B1 (pt) 2020-03-17
JP5622885B2 (ja) 2014-11-12
AU2002319049B2 (en) 2007-10-25
PL368912A1 (en) 2005-04-04
JP2005507647A (ja) 2005-03-24
US20030109437A1 (en) 2003-06-12
CA2453965A1 (en) 2003-01-30
WO2003008444A2 (en) 2003-01-30
PT1417228E (pt) 2007-05-31
IL159903A0 (en) 2004-06-20
NO20040222L (no) 2004-03-19
WO2003008443A2 (en) 2003-01-30
KR20040018481A (ko) 2004-03-03
DK1417228T3 (da) 2007-06-04
BR0211199A (pt) 2004-10-26
US7192929B2 (en) 2007-03-20
ES2281529T3 (es) 2007-10-01
EA006603B1 (ru) 2006-02-24
AU2002319050B2 (en) 2008-09-11
JP2005506061A (ja) 2005-03-03
ES2281528T3 (es) 2007-10-01
CY1108009T1 (el) 2013-09-04
MXPA04000561A (es) 2005-02-17
DE60218179D1 (de) 2007-03-29
ZA200401320B (en) 2005-01-26
NO333999B1 (no) 2013-11-11
JP4587667B2 (ja) 2010-11-24
DE60218179T2 (de) 2007-11-22
NZ531115A (en) 2005-03-24
DE60217507T2 (de) 2007-11-15
CN100475843C (zh) 2009-04-08
BRPI0211200B8 (pt) 2021-07-27
WO2003008443A3 (en) 2003-11-27
KR20040026686A (ko) 2004-03-31
JP2011152133A (ja) 2011-08-11
EP1417227A2 (en) 2004-05-12
EP1417227B1 (en) 2007-01-10
US20030096756A1 (en) 2003-05-22
EA200400205A1 (ru) 2004-06-24
NZ531114A (en) 2006-12-22
PL207588B1 (pl) 2011-01-31
EP1417228A2 (en) 2004-05-12
BR0211200A (pt) 2004-09-28
CA2453965C (en) 2016-01-19
US7241738B2 (en) 2007-07-10
EP1417228B1 (en) 2007-02-14

Similar Documents

Publication Publication Date Title
KR100966232B1 (ko) 종양 및 세포의 제거 또는 파괴를 필요로 하는 다른질환의 치료에 효과적인 펩티드
KR101375026B1 (ko) 종양 및 세포의 제거 또는 파괴를 필요로 하는 다른 질환의 치료에 효과적인 펩티드
KR100945383B1 (ko) 종양 및 세포의 제거 또는 파괴를 필요로 하는 다른질환의 치료에 효과적인 펩티드
AU2002319049A1 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
AU2002319050A1 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
KR20080110765A (ko) 종양 및 세포의 제거 또는 파괴를 필요로 하는 기타 상태의치료에 효과적인 펩티드
KR100632903B1 (ko) 신경 사 단백질을 사용하여 종양 및 세포의 제거 또는파괴를 필요로 하는 다른 증상을 치료하는 방법
AU2002256587A1 (en) Peptides derived from neural thread proteins and their medical use
CN100432103C (zh) 有效治疗肿瘤和其它需要除去或破坏细胞的疾病的肽
EP1714979A2 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
EP1847550A2 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
HK1110083A (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
HK1097281A (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040119

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070719

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20090423

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20100226

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20090423

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20100401

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20100226

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20100601

Appeal identifier: 2010101002452

Request date: 20100401

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20100429

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20100401

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20100401

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20091023

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20070719

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20100601

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20100507

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20100617

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20100617

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20130708

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20130708

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20140609

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20140609

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20150519

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20150519

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20161212

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20161212

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20171213

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20171213

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20201202

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20211027

Start annual number: 12

End annual number: 12

PC1801 Expiration of term

Termination date: 20230119

Termination category: Expiration of duration

PR1001 Payment of annual fee

Payment date: 20221213

Start annual number: 13

End annual number: 13